Singapore markets close in 2 hours 29 minutes

argenx SE (ARGX.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
353.60-2.30 (-0.65%)
At close: 05:35PM CEST

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
31 10 703 8441

Full-time employees1,148

Key executives

NameTitlePayExercisedYear born
Mr. Timothy Van Hauwermeiren EMBA, M.Sc.CEO & Executive Director1.2MN/A1972
Mr. Karl GubitzChief Financial Officer785.2kN/A1970
Ms. Karen MasseyChief Operating Officer1.32MN/A1979
Mr. Filip BorgionsVP & Global Head of Technical OperationsN/AN/AN/A
Mr. Peter UlrichtsChief Scientific OfficerN/AN/A1980
Ms. Beth DelGiaccoVP and Global Head of Corporate Communications & Investor RelationsN/AN/AN/A
Ms. Malini MoorthyGeneral CounselN/AN/A1970
Mr. Arjen Lemmen M.Sc.Vice President of Corporate Development & StrategyN/AN/A1985
Mr. Marc SchorpionGlobal Head of Human ResourcesN/AN/A1959
Ms. Andria WilkGlobal Head of QualityN/AN/A1974
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Corporate governance

argenx SE’s ISS governance QualityScore as of 1 June 2024 is 5. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.